Traumatic Brain Injury Market: Epidemiology, Therapies, Companies, DelveInsight | veriNOS pharmaceuticals GmbH, Cellvation, Abalonex, Hope Biosciences
Some
of the key facts of the Traumatic Brain Injury Market Report:
- The
global traumatic brain injury (TBI) market is projected to experience
steady growth from 2025 to 2034, largely fueled by the development of
innovative therapies. According to DelveInsight, there were approximately
4.3 million new TBI cases across the 7MM (United States, EU5, and Japan)
in 2024, with numbers expected to rise throughout the forecast period. The
United States reported the highest incidence, followed by Japan, Germany,
France, and the United Kingdom.
- In
terms of market value, the U.S. led in 2024, with standard care generating
around USD 1.12 billion. Current treatment approaches primarily involve
off-label use of medications, including antidepressants, antiepileptics,
antipsychotics, analgesics, antacids, and other symptom-relief drugs.
Notably, 45–85% of TBI patients rely on psychotropic and pain medications,
underscoring the high dependence on pharmacologic management.
- Promising
therapies, such as AKUUGO for chronic TBI, have received multiple
regulatory designations recognizing their potential. Emerging treatments
like ONP-002, CEVA101, OXE103 (Ghrelin), HB-AdMSCs, MR-301, NE3107a, and
others are expected to transform the TBI treatment landscape and drive
market expansion. Companies including Oragenics, Beyond Barriers
Therapeutics, Noveome, and Neuroplast are exploring innovative delivery
methods, such as intranasal and intrathecal administration.
- There
is increasing recognition of the need to address both psychiatric and
non-neurological symptoms in TBI patients, particularly among females, and
to carefully assess medication regimens to mitigate risks associated with
polypharmacy. As research advances and new therapies gain approval, the
TBI market is poised for significant growth over the next decade.
- In
2024, the United States recorded an estimated 3,042,000 TBI cases, the
highest among the 7MM. Within the EU4 and the UK, Germany had the highest
number of cases, followed by France, while Spain reported the lowest. In
the UK specifically, approximately 125,000 adults and 49,000 children were
affected.
- Regulatory
progress has also enhanced diagnostic capabilities. On April 2, 2024, the
FDA approved Abbott’s i-STAT TBI cartridge—a portable, whole-blood tool on
the Alinity platform—providing lab-quality results in just 15 minutes to
support concussion assessment and reduce unnecessary CT scans.
- Key
companies actively advancing TBI treatments include veriNOS
Pharmaceuticals GmbH, Cellvation, Abalonex, and Hope Biosciences.
Collectively, these emerging therapies and innovations are expected to
reshape the TBI market landscape in the coming years.
Traumatic
Brain Injury Overview
Traumatic
brain injury (TBI) occurs when the brain sustains sudden damage due to a strong
blow or jolt to the head. Common causes include motor vehicle accidents, falls,
sports-related impacts, and physical assaults. The severity of TBI can range
from mild concussions to serious injuries that result in long-term brain
impairment. The immediate damage caused at the time of impact is known as the
primary injury, which may affect a specific part of the brain or the brain as a
whole. While skull fractures can occur, they are not always present. The brain
may collide with the inner skull during trauma, causing bruising, bleeding, and
damage to nerve fibers.
Symptoms
of TBI vary according to injury severity and are typically categorized as mild,
moderate, or severe. Mild TBI may involve brief loss of consciousness or no
loss at all, with symptoms such as headache, dizziness, confusion, blurred
vision, fatigue, ringing in the ears, sleep disturbances, mood or behavioral
changes, and difficulties with memory or concentration.
Moderate
to severe TBI symptoms are more pronounced and can include persistent or
worsening headaches, repeated nausea or vomiting, seizures, inability to
awaken, enlarged pupils, slurred speech, limb weakness or numbness, poor
coordination, and heightened confusion or agitation.
Traumatic
Brain Injury Market Outlook
Management
of traumatic brain injury (TBI) typically involves a combination of medical
care, rehabilitation, and supportive therapies designed to alleviate symptoms
and promote recovery. Treatment strategies vary widely based on the injury’s
severity, ranging from standard cognitive therapy sessions to more complex
procedures, such as bilateral decompressive craniotomies. While clinical
guidelines provide a framework for TBI care, they must be tailored to the
individual patient’s specific needs and circumstances.
📌 Visit Us:
🌐
Website: //statisticsaward.com/
🏆 Nomination: //statisticsaward.com/award-nomination/
📝 Registration: //statisticsaward.com/award-registration/
Comments
Post a Comment